TWO · 6620.TWO
Handa Pharmaceuticals, Inc.
NT$132.50-NT$5.00 (-3.64%)
Handa Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
Loading market information…
TWO · 4166.TWO · TWD
Stock price, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Orient Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Orient Pharma Co., Ltd.’s next earnings report is currently expected on Nov 17, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Orient Pharma Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Orient Pharma Co., Ltd., established in Taipei, Taiwan, in 2008, is a global pharmaceutical company engaged in the research, development, production, and sales of medicinal products. Its extensive pipeline addresses diverse therapeutic areas, including psychiatric disorders such as anti-psychotics and psychostimulants, neurological conditions like Parkinson's and Alzheimer's diseases, and treatments for sialorrhea, tuberculosis, and attention deficit hyperactivity disorder (ADHD). Beyond its drug portfolio, the company is also at the forefront of developing advanced drug delivery technologies, featuring multi-stage controlled release systems, transdermal patches, orally disintegrating tablets, sustained-release formulations, and microgranule technology.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$132.50-NT$5.00 (-3.64%)
Handa Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.52% below the high.
NT$28.80-NT$0.15 (-0.52%)
Synmosa Biopharma Corporation’s quoted price sits in the lower half of its reported 52-week range, 8.54% below the high.
NT$56.70-NT$0.20 (-0.35%)
Standard Chem & Pharm Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.36% below the high.
NT$30.55-NT$0.20 (-0.65%)
Sinphar Pharmaceutical Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 6.86% below the high.
NT$84.00-NT$1.00 (-1.18%)
Alar Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.5% below the high.
NT$50.00-NT$1.80 (-3.47%)
Panion & Bf Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.55% below the high.
NT$43.50-NT$0.30 (-0.68%)
Orient EuroPharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 12.3% below the high.
NT$19.70-NT$0.60 (-2.96%)
Anxo Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.57% below the high.
